These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17162252)

  • 21. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
    Brewer GJ
    Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
    Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
    Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
    Zhang L; Lichtmannegger J; Summer KH; Webb S; Pickering IJ; George GN
    Biochemistry; 2009 Feb; 48(5):891-7. PubMed ID: 19146437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
    Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
    Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetrathiomolybdate is effective in a mouse model of arthritis.
    McCubbin MD; Hou G; Abrams GD; Dick R; Zhang Z; Brewer GJ
    J Rheumatol; 2006 Dec; 33(12):2501-6. PubMed ID: 17143984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
    Brewer GJ
    Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
    Brewer GJ
    J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risks of free copper in the body and the development of useful anticopper drugs.
    Brewer GJ
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):727-32. PubMed ID: 18827576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of graded levels of iron, zinc, and copper supplementation in diets with low-phytate or normal barley on growth performance, bone characteristics, hematocrit volume, and zinc and copper balance of young swine1.
    Veum TL; Ledoux DR; Shannon MC; Raboy V
    J Anim Sci; 2009 Aug; 87(8):2625-34. PubMed ID: 19359503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
    Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
    Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
    Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
    J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin.
    Xu Y; Choi J; Hylander B; Sen A; Evans SS; Kraybill WG; Repasky EA
    Int J Hyperthermia; 2007 Sep; 23(6):513-27. PubMed ID: 17952765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after Doxorubicin treatment in rats.
    Santos RV; Batista ML; Caperuto EC; Costa Rosa LF
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1294-9. PubMed ID: 17973871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.
    Gabrielson K; Bedja D; Pin S; Tsao A; Gama L; Yuan B; Muratore N
    Cancer Res; 2007 Feb; 67(4):1436-41. PubMed ID: 17308081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on protective effects of Panax notoginseng saponins on doxorubicin-induced myocardial damage].
    Shi R; Liu L; Huo Y; Cheng YY
    Zhongguo Zhong Yao Za Zhi; 2007 Dec; 32(24):2632-5. PubMed ID: 18338604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.